Pinkerton Retirement Specialists’s Galectin Therapeutics GALT Stock Holding History

Pinkerton Retirement Specialists’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$6K	–	95
2018 Q3	$6K	Hold	1,000	–	–	﹤0.01%	149
2018 Q2	$6K	Hold	1,000	–	–	﹤0.01%	158
2018 Q1	$5K	Hold	1,000	–	–	﹤0.01%	147
2017 Q4	$4K	Hold	1,000	–	–	﹤0.01%	176
2017 Q3	$2K	Hold	1,000	–	–	﹤0.01%	146
2017 Q2	$2K	Hold	1,000	–	–	﹤0.01%	166
2017 Q1	$2K	Hold	1,000	–	–	﹤0.01%	104
2016 Q4	$1K	Hold	1,000	–	–	﹤0.01%	560
2016 Q3	$1K	Hold	1,000	–	–	﹤0.01%	554
2016 Q2	$1K	Buy	+1,000	New	+$1.47K	﹤0.01%	560

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinkerton Retirement Specialists's GALT Position: Q4 2018 in Review

Pinkerton Retirement Specialists sold out of Galectin Therapeutics (GALT) in Q4 2018, closing a stake of 1,000 shares — an estimated $6K sold.

Pinkerton Retirement Specialists first reported a position in GALT in Q2 2016 and held it in 10 quarters. The position peaked at $6K in Q3 2018. 61 funds tracked by Wall St. Rank hold GALT as of Q4 2018.

Pinkerton Retirement Specialists reported no remaining Galectin Therapeutics position as of Q4 2018 after selling out during the quarter.
Pinkerton Retirement Specialists sold 1,000 Galectin Therapeutics shares in Q4 2018, an estimated $6K.
Pinkerton Retirement Specialists first reported a position in Galectin Therapeutics in Q2 2016 and held it in 10 quarters.
Pinkerton Retirement Specialists's Galectin Therapeutics position peaked at $6K in Q3 2018.
61 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2018.

Based on Pinkerton Retirement Specialists's 13F filing for Q4 2018, filed 15 Feb 2019.